Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucocort
- Development stage
- Unknown
- Lead developer
- Mucocort
- Administration
- Topical
01
Overview
Mucocort (M045A) is a self-absorbing, mucoadhesive intra-oral patch developed by Mucocort AB for the treatment of recurrent aphthous stomatitis (RAS), commonly known as mouth ulcers. Classified as a Class II medical device under the EU Medical Device Regulation (MDR), the patch works through a hygroscopic (moisture-absorbing) mechanism, adhering to the mucosal surface to form a physical shield over the ulcer. This barrier provides immediate and long-lasting pain relief by protecting the sensitive area from external stimuli and promotes faster healing. The product is currently in Phase III clinical trials in Sweden, with production managed by Aurena Laboratories AB.
- Brand names
- Mucocort
Beyond the preview
Go deeper on Mucocort.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucocort.